The association of PD-L1 and cancer stem cells warrant further studies in ovarian cancer recurrence, which we believe will lead to the predictive biomarkers for ovarian cancer recurrence and developing a proper treatment strategy. This evidence concerns the gene CD274 and ovarian carcinoma.